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Reviews (CDSR) 2019, Issue 2, DOI: 10.1002/14651858.CD010406. (see www.cochranelibrary.com 
for information). Cochrane Reviews are regularly updated as new evidence emerges and in 






Corticosteroids may be beneficial in sepsis but uncertainty remains over their effects in 
severe influenza. This systematic review updates the current evidence regarding 
corticosteroids in the treatment of influenza and examines the effect of dose on 
outcome. 
Data Sources 
Electronic databases (MEDLINE, EMBASE, CINAHL, LILACS, CENTRAL, Web of Science) 
and trial registries were searched to October 2018 for randomised controlled trials 
(RCTs), quasi-experimental designs and observational cohort studies reporting 
corticosteroid versus no corticosteroid treatment in individuals with influenza.  
Study Selection and Data Extraction 
Two researchers independently assessed studies for inclusion. Risk of bias was assessed 
using the Cochrane Risk of Bias tool (RCTs) or Newcastle-Ottawa Scale (observational 
studies). Where appropriate, we estimated the effect of corticosteroids by random 
effects meta-analyses using the generic inverse variance method. Meta‐regression 
analysis was used to assess the association of corticosteroid dose and mortality.  
Data Synthesis 
We identified 30 eligible studies, all observational apart from one RCT. Twenty-one 
observational studies were included in the meta-analysis of mortality, which suggested 
an adverse association with corticosteroid therapy (Odds ratio (OR) 3.90, 95% 
confidence interval (CI) 2.31 to 6.60, 15 studies; adjusted hazard ratio  1.49, 95% CI 
1.09 to 2.02, 6 studies). Risk of bias assessment was consistent with potential 
confounding by indication. Pooled analysis of seven studies showed increased odds of 
hospital-acquired infection in people treated with corticosteroids (unadjusted OR 2.74, 
95% CI 1.51 to 4.95).  
3 
 
Meta-regression of the effect of dose on mortality did not reveal an association, but 
reported doses of corticosteroids in included studies were high (mostly >40 mg 
methylprednisolone (or equivalent) per day). 
Conclusions 
Corticosteroid treatment in influenza is associated with increased mortality and hospital-
acquired infection, but the evidence relates mainly to high corticosteroid doses and is of 






Induction of proinflammatory cytokines correlates with symptoms and fever in acute 
influenza (1), with significantly elevated levels in severe influenza (2-4). Endogenous 
corticosteroids, produced principally by the adrenal glands and regulated by the 
hypothalamic-pituitary-axis (HPA), possess anti-inflammatory, immunomodulatory and 
vascular properties (5-7). However, a combination of proinflammatory cytokine inhibition 
of the HPA, substrate deficiency, damage to the adrenal glands and peripheral 
corticosteroid resistance could result in adrenal insufficiency during critical illness (8, 9). 
Based upon the physiological rationale and evidence from a systematic review 
incorporating the latest clinical trials (10), a recent ‘Rapid Recommendation’ makes a 
weak recommendation to give corticosteroids to people with sepsis,  with the proviso 
that it is also reasonable not to prescribe them due to uncertainty of their benefit. The 
optimal dose of corticosteroids in sepsis remains uncertain (11).   
 Although moderate quality evidence from randomised controlled trials (RCTs) 
suggests reduced mortality in severe community-acquired pneumonia (CAP) treated with 
corticosteroids (12), their role in influenza virus infections has been highly controversial. 
During the 2009 pandemic, 9% of hospitalised patients and up to 69% of critically-ill 
intensive care unit (ICU) admissions with influenza received corticosteroids (13-16); 
subsequent analysis indicated no benefit or even increased mortality with corticosteroid 
use.  
Meta-analysis of ten studies in the original version of this systematic review, 
suggested that corticosteroid therapy for presumed influenza-associated complications is 
associated with increased risk of mortality (17). All included studies were observational 
with confounding by indication a major concern. In light of the ongoing controversy and 
subsequent publication of additional individual studies, we have updated this systematic 
review which, together with evaluation of data on the effect of corticosteroid dose on 
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mortality, aims to summarise the current evidence, highlight important clinical 
uncertainties and subsequently inform the design of future studies to help definitively 
address these areas. 
 
Methods 
We conducted this updated systematic review in accordance with the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (18) and Meta-Analysis of 
Observational Studies in Epidemiology guidelines (19).  The original study protocol was 
registered with the Cochrane Database of Systematic Reviews 
(http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010406/abstract). 
Study Eligibility 
Randomised controlled trials, quasi-experimental designs and observational cohort 
studies reporting the effect of corticosteroid treatment versus no corticosteroid 
treatment in people with clinically-diagnosed influenza or influenza-like illness and/or 
laboratory-confirmed influenza were eligible. The intervention was intravenous or oral 
corticosteroid of any type, dose or duration, given for any clinical reason but coinciding 
with influenza confirmed by positive RT-PCR, viral culture or rapid antigen test in  
respiratory specimens. 
The primary outcomes were 30-day mortality and rate of admission to ICUs. 
Secondary outcomes were 30-day readmission after hospital discharge, the proportion of 
people requiring mechanical ventilation, length of hospital stay, and adverse events 
secondary to corticosteroid use, including hospital-acquired infections as defined by 
individual studies. 
Search Methods and Data Extraction 
We searched MEDLINE, EMBASE, CINAHL, LILACS , Cochrane Central Register of 
Controlled Trials (CENTRAL), and Web of Science from inception to October 2018, and 
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the following trial registries (October 2018): ISRCTN (http://www.isrctn.com/); World 
Health Organization International Clinical Trials Registry Platform 
(http://www.who.int/ictrp); and ClinicalTrials.gov (www.clinicaltrials.gov). The Cochrane 
Highly Sensitive Search Strategy was used to identify RCTs (20), and the Scottish 
Intercollegiate Guidelines Network filter to identify observational studies (21). The 
search strategy included core search terms relating to influenza and corticosteroids 
(Supplementary Table 1).  
In a three-stage screening process two authors independently assessed the titles, 
abstracts and full-text of retrieved articles for potential inclusion. Data extraction was 
done independently by two authors with arbitration by a third author as required. The 
risk of bias was evaluated at outcome level using the Cochrane Collaboration tool for 
RCTs and Newcastle-Ottawa Scale (NOS) for observational studies (22, 23). Overall 
quality of the evidence for the main outcomes of interest was assessed using the 
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) 
framework (24). 
Data Analysis 
Dichotomous outcome data from individual studies were extracted as tabulated data 
from which risk ratios (RRs) or odds ratios (ORs) with 95% CIs were estimated. We 
extracted adjusted outcome measures as ORs or hazard ratios (HRs) with 95% CIs and 
presented these separately in pooled analyses. Where appropriate we estimated the 
effect of corticosteroids by random effects meta-analyses of pooled crude and adjusted 
ORs and pooled adjusted HRs for each outcome measure compared to no corticosteroids 
using the generic inverse variance method using Review Manager [Computer program], 
Version 5.3 (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 
2014). Heterogeneity was assessed using the I2 statistic. Publication bias was assessed 
using funnel plots for meta-analyses containing ten or more studies.  
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To explore the putative interaction between corticosteroid dose and the 
magnitude of effect, we performed a meta‐regression analysis using post-admission 
mortality as the dependent variable, and dose of corticosteroids as predictors. We 
performed random effects meta‐regression analyses using the metareg command in 
Stata version 15.1 (Stata Corp, College Station, Texas).   
Results 
Study characteristics 
We identified 3686 articles; of the 30 articles meeting the inclusion criteria, 21 were 
included in the meta-analysis of mortality (15, 25-44) and nine were included in the 
narrative synthesis only (45-53)(Figure 1). There was one RCT and the remainder were 
observational studies (99,224 individuals). The characteristics of included studies are 
summarised in supplementary table 2.  
The median age of the cohort or corticosteroid-treated groups ranged from 2.5 to 
63 years. One study included children only (31), the others included either adults only or 
people of mixed ages but predominantly adults.  Disease severity at baseline was 
recorded in nine studies (15, 28, 30, 34, 36-38, 42, 49), five of which recorded higher 
baseline disease severity in the corticosteroid- treated group compared to the untreated 
group (30, 34, 36-38). Ten studies included only patients admitted to ICU (15, 27, 28, 
30, 36-38, 40, 41, 44), with the remaining studies having mixed data for both ICU–
admitted and non-ICU hospitalised patients. 
Thirteen studies reported the doses or regimens of administered corticosteroids, 
with median/mean doses ranging from 40 to 141mg/day of methylprednisolone 
equivalent in ten studies (15, 26, 28, 30, 34, 36, 38, 39, 43, 52), and regimens of 1-6 
mg/kg/day in three studies (35, 37, 51). Median duration of corticosteroid therapy in 
seven studies ranged from 5.1 to 11.0 days.  
8 
 
The risk of bias assessments for 46 reported outcomes from 30 observational 
studies and the one RCT are summarised in supplementary table 3 and supplementary 
figure 1. For the RCT (52), the methods of randomisation, allocation concealment and 
blinding were judged to be adequate. The maximum number of stars for the selection, 
comparability and outcome domains was achieved in 28, 14 and 36 of the 46 outcomes 
respectively. A high degree of correlation between corticosteroid treatment and potential 
confounders such as disease severity and co-morbid conditions was noted in several 
studies (28, 30, 34, 36, 42).  
Effect on mortality 
The nineteen studies of influenza A(H1N1)pdm09 conducted solely during the 2009 
pandemic (15, 25, 27, 28, 30, 31, 33, 34, 36, 37, 39, 40, 42-44, 46, 48, 49, 51), and 
five studies of seasonal/mixed seasonal and pandemic strains of influenza (29, 32, 38, 
41, 52) reported either no difference or greater mortality associated with corticosteroid 
therapy. The single study of influenza A(H5N1) found an association between 
corticosteroid use and increased mortality after adjusting for neutropenia as a marker of 
disease severity (35). A study of influenza A(H7N9) reported no overall association with 
30-day mortality although on subgroup analysis increased mortality and prolonged viral 
shedding were associated with high doses of corticosteroids (>150mg/day 
methylprednisolone equivalent) compared to no corticosteroids (26). 
Reported timing of mortality from admission was inconsistent so stratification by 
30-day mortality was not possible. Meta-analysis of 15 studies (2212 participants) 
showed significantly greater odds of mortality with corticosteroid use with moderate 
statistical heterogeneity (OR 3.90, 95% CI 2.31 to 6.60, I2=68%)(Supplementary figure 
2). On subgroup analysis both unadjusted and adjusted OR estimates showed an 
association between corticosteroid treatment and mortality (unadjusted OR 4.69, 95% 
CI 2.35 to 9.79, I2=67%; adjusted OR 2.23, 95% CI 1.54 to 3.24, I2=0%). An 
association with corticosteroid use was also found when the results of six studies 
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reporting adjusted HRs (aHR) were pooled (aHR 1.49, 95% CI 1.09 to 2.02, 
I2=68%)(Supplementary figure 3).  
Increased risk of mortality in people treated with corticosteroids was observed in 
subgroup analysis of the ten studies that only included ICU-admitted critically-ill patients 
(OR 2.43, 95% CI 1.72 to 3.43, I2=0%, 7 studies, n=1295; adjusted HR 1.70, 95% CI 
1.14 to 2.54, I2=60%, 3 studies, n=2246)(Figures 2a and 2b). The risk was also raised 
in the subgroup containing eight studies reporting ORs that had a mixed ICU/non-ICU 
population (OR 4.72, 95% CI 2.07 to 10.77, I2= 70%), although for the three studies 
reporting aHR, the risk was not significantly increased (aHR 1.31, 95% CI 0.73 to 2.35, 
I2=69%). Three studies analysed patients with acute respiratory distress syndrome 
(ARDS) separately, with pooled analysis indicating increased risk of death in the group 
treated with corticosteroids (OR 2.32, 95% CI 1.36 to 3.95, I2= 0%, n=392)(15, 30, 
36). Pooled data for people who did not have ARDS from two of these studies showed a 
non-significant trend towards increased mortality risk with corticosteroid treatment (OR 
2.54, 95% CI 0.77 to 8.39), with no significant subgroup difference between those with 
ARDS and no ARDS (p=0.89)(supplementary figure 4)  A subgroup analysis of patients 
who were in shock versus those not in shock on admission to ICU was conducted in one 
study (38), with increased mortality risk associated with corticosteroid treatment in both 
groups (OR 1.60, 95% CI 1.21 to 2.13 and OR 1.89, 95% CI 1.22 to 2.95 respectively), 
with no significant difference between the subgroups (p=0.53).  
The potential effect of corticosteroids at baseline for the treatment of pre-existing 
underlying conditions was considered in five studies , and patients were either excluded 
at the outset if they were receiving corticosteroids for chronic conditions (15, 28, 38) or 
a separate analysis was done of people who had not received prior corticosteroids (30, 
32). Pooled analysis of data from only these patients showed a significant association 
between adjunctive corticosteroid treatment and risk of mortality (OR 2.01, 95% CI 1.39 




Funnel plot analysis did not reveal clear evidence of publication bias in the 21 
studies included in the meta-analyses (Supplementary figure 5). We graded the certainty 
of the evidence specific to mortality as very low (supplementary table 4). 
Three studies categorised corticosteroid dose as low or low/moderate and high. 
One study comparing low-dose (defined as <80 mg/day methylprednisolone equivalent) 
with higher corticosteroid doses found no difference in mortality risk (p=0.854)(43). A 
second study (288 participants) reported that compared to controls, patients receiving 
high-dose corticosteroids (>150 mg/day methylprednisolone equivalent) had increased 
mortality (HR 3.05, 95% CI 1.28 to 7.25, p=0.012), whereas in those treated with low 
to moderate dose corticosteroids the risk was not significantly different (HR 1.64, 95% 
CI 0.79 to 3.39, p=0.183)(26). In the third study (34), a large cohort of 2141 people, no 
overall effect of corticosteroids on mortality was found (HR 0.80, 95% CI 0.56 to 1.15), 
although when patients were stratified according to their disease severity as measured 
by their hypoxic status, low-moderate dose corticosteroids (25-150 mg/day 
methylprednisolone equivalent) were associated with decreased mortality in hypoxic 
people (PaO2/FiO2 <300mm/Hg), whereas high-dose corticosteroids had no beneficial 
effect in this group (HR 0.49, 95% CI 0.32 to 0.77, p=0.02 and HR 0.88, 95% CI 0.56 to 
1.39, p=0.58 respectively). Neither low-moderate dose nor high-dose corticosteroids had 
a significant effect on 30-day mortality in non-hypoxic people.  
Ten studies with data on corticosteroid dose were included in a random-effects 
meta-regression analysis (15, 26, 28, 30, 34, 36, 38, 39, 43, 52). Median daily dose was 
reported in seven of the studies, two reported total daily dose and one reported mean 
daily dose only. No significant interaction was observed between daily corticosteroid 
dose and mortality risk (regression co-efficient -0.0032; p=0.745) (Figure 3). 
ICU Admission, Mechanical Ventilation, Length of Stay and Hospital-Acquired Infection 
Studies reporting these outcomes are summarised in Table 1.  
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Seven studies presented data on the association between corticosteroid use and 
hospital-acquired infections. The definition of hospital-acquired infection varied but most 
studies reporting this outcome broadly defined it as the positive culture of a new 
pathogen (bacterial or fungal) from lower respiratory tract or blood cultures ≥48 hours 
after admission, and did not report results for different potential sources of infection 
separately. On pooled analysis, the overall risk of non-specific hospital-acquired infection 
was increased in patients treated with corticosteroids (OR 2.74, 95% CI 1.51 to 4.95, 
n=12,114)(supplementary figure 6), although all included estimates were unadjusted for 
potential confounders and statistical heterogeneity was high (I2=90%). Subgroup 
analysis of three studies which included only ICU-admitted patients showed a trend 
towards increased risk of infection in corticosteroid treated patients, but was not 
statistically significant (OR 2.10, 95% CI 0.98 to 4.52, I2 = 86%, n=1028, p=0.06).  
Two ICU-based studies reported ventilator-associated pneumonia (VAP) 
separately (15, 38). Pooled analysis of unadjusted data suggested a non-significant 
trend toward increased risk of VAP with corticosteroids (OR 1.44, 95% CI 0.91 to 2.27, 
I2=44%, n=2054, p=0.12).  
For hospital-acquired infection we graded the certainty of the evidence as very 
low (supplementary table 4). 
 
Discussion 
Our updated systematic review and meta-analysis is, to our knowledge, the most 
comprehensive analysis to date to investigate the effect of corticosteroids on clinical 
outcomes in people with confirmed influenza. The majority of the data are from 
observational studies and although we included one eligible RCT, it was not powered for 
mortality and had only a very small number of participants with confirmed influenza. Our 
main finding is that analysis of observational data suggests an association between 
corticosteroid treatment and increased risk of mortality.   
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Overall the quality of the evidence is very low and there are important 
considerations to take into account when interpreting the findings. Firstly, many of the 
included studies did not specify the indications for corticosteroid therapy. Some studies 
stated the rationale for giving corticosteroids therapy as adult respiratory distress 
syndrome (ARDS) and septic shock (15, 30, 43) and it is possible at one extreme that 
corticosteroids were only given to the sickest patients or those with refractory illness as 
a final attempt to treat. This is suggested from our subgroup analysis of studies that had 
separate data for ARDS and non-ARDS patients in which the mortality risk was only 
significantly elevated in the ARDS subgroup. No significant difference was noted between 
people who were shocked on admission to ICU and those who were not, although data 
were very limited with only one included study having separate data for shock. 
Conversely, corticosteroids may have been used to treat less severe comorbid diseases 
such as exacerbations of asthma, and although some of the included studies excluded 
patients who may have received prior corticosteroids for pre-existing conditions, or 
conducted a separate analysis of such patients, most did not. 
A further important consideration relates to the dose of corticosteroid used. In 
our meta-regression we found no clear evidence of an association between the overall 
dose of corticosteroid and the risk of mortality. However, dose and duration of 
corticosteroids were poorly specified in many of the studies, and where reported, median 
doses were generally considerably higher than the dose typically recommended for the 
treatment of septic shock or exacerbations of airways disease such as asthma (54-56). 
Variability in corticosteroid dose and administration schedule are both factors that have 
been associated with treatment outcomes in the setting of severe sepsis; in particular 
high doses given in short bursts have not been associated with benefit compared to low 
doses given for longer duration (≥ 5 days)(57). A recent subgroup analysis of  RCTS in 
sepsis did not find any credible effect modification with corticosteroid dose, although 
most of the evidence was from studies using hydrocortisone with or without 
fludrocortisone at low dose (<400 mg/d hydrocortisone or equivalent) and over a long 
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duration (>2 days)(10). RCTs of corticosteroids in CAP have typically used much lower 
doses (32mg-40mg methylprednisolone equivalent) (12) than we noted in our included 
studies. Data from studies using low-dose steroids (≤40 mg/day MP equivalent) were 
lacking in our review. As the doses in our review were typically high, we cannot exclude 
the possibility that low-dose corticosteroids may have a different effect on mortality, or 
that there may be particular patient subgroups in whom their use may indeed be of 
benefit, as suggested by some of the individual included studies (26, 34). The use of 
higher doses of corticosteroids may also explain the greater risk from hospital-acquired 
infections which we noted. Corticosteroid use has been reported to be an independent 
risk factor for the development of invasive fungal infections in adults admitted to ICUs 
with influenza (58). Additionally, there is weak evidence from a recent observational 
study that influenza infection and corticosteroid treatment are both independent risk 
factors for the development of invasive pulmonary aspergillosis which is itself associated 
with high mortality (59). 
The evidence base from clinical trials of corticosteroids in the setting of sepsis and 
pneumonia contrast with the findings from our review. Specifically, recent meta-analysis 
of prolonged low-dose corticosteroids in sepsis (which included two recent large RCTs, 
the Activated Protein C and Corticosteroids for Human Septic Shock (APROCCHSS) 
trial(60) and the Adjunctive Glucocorticoid Therapy in Patients with Septic Shock 
(ADRENAL) trial (61)) concluded that corticosteroids may achieve a small reduction or no 
reduction in the risk of dying in the short-term with a possible small decrease in longer-
term mortality (60 days to 1 year)(10). Thus there is strong evidence from RCTS that 
corticosteroids in sepsis do not have a large positive effect.   In the setting of CAP (not 
specifically influenza), an association between corticosteroid therapy and decreased 
mortality, need for mechanical ventilation and hospital length of stay has been shown 
(62). Other systematic reviews have also demonstrated a beneficial effect of 
corticosteroids on mortality and other clinical outcomes, but only in people with severe 
CAP (12, 63-66). Subgroup analyses by individual aetiological pathogens were not 
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possible in these systematic reviews due to lack of separation of outcome data by 
pathogen or lack of microbiological confirmation in the included studies. Large trials of 
corticosteroids in severe pneumonia are currently underway and should provide more 
robust data in the next few years (67, 68).  
Limitations of our review include the current lack of evidence from relevant RCTs. 
Although we did not restrict our inclusion criteria to particular patient demographics, 
study settings or influenza subtype, we identified only one RCT which was not directly 
relevant to our review question. There was a high correlation between corticosteroid 
therapy and potential confounders for measured outcomes, such as disease severity and 
comorbid illnesses, so confounding by indication is likely to be a significant bias in 
studies which only provided unadjusted effect estimates. Additionally, time to 
hospitalization, antiviral use, presence of respiratory failure prior to corticosteroids, and 
the rationale for corticosteroid use were sparsely reported across studies. Clinical 
heterogeneity between the studies was also apparent in the measurement of disease 
severity with a range of clinical risk scores used, reported timing of mortality, types and 
doses of corticosteroids, and the consistency of use of co-interventions such as antivirals 
and antibiotics. Our meta-regression analysis of corticosteroid dose was limited by the 
lack of studies with data for low-dose corticosteroids, and there was also variation of 
doses used within the included studies. However, we believe that it is valuable in that it 
highlights an important gap in the evidence, and particularly so in light of meta-analyses 
of corticosteroids in sepsis and CAP, where low-dose steroids may have some beneficial 
clinical effects.  
Conclusions 
This systematic review highlights that the current evidence base is still not strong 
enough to make firm recommendations regarding the effectiveness or otherwise of 
corticosteroids as adjunctive treatment in people with proven influenza. Discrepancies 
remain between the findings in influenza and other clinical situations, but there are 
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important differences in terms of study designs and doses of corticosteroids used. The 
question of whether low doses of corticosteroids may be of some benefit in particular 
subgroups of patients with influenza requires further study and there is a clear need for 
well-designed RCTs to examine the effects of corticosteroids on clinical outcomes, 
particularly addressing the effects of low-dose corticosteroids and to include severely ill 
patients with influenza complications including primary viral pneumonia, septic shock 
and ARDS. This supports the updated World Health Organization Research Agenda 
recommendations for optimising the treatment of patients with influenza (69). In the 
meantime our results continue to support existing WHO recommendations (70) that 
systemic corticosteroids should be avoided in influenza patients unless indicated for 
other reasons or as part of an approved research protocol. In the current absence of 
finer details regarding the risks associated with subcategories of critically-ill influenza 
patients, and given the concerns regarding invasive secondary infections, caution should 
at the very least be applied before offering corticosteroids to anyone with severe 
influenza and it is not advisable to routinely give them to such patients.   
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Figure 1 Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) 
flow diagram for the article selection process 
Figure 2a and 2b  Meta-analysis of studies reporting mortality stratified by ICU 
admission status.     
 Figure 2a Odds Ratios (ORs) 
 Figure 2b Hazard Ratios (HRs)                                         
Footnote for figure 2: Mortality estimates determined using random effects modelling.  
CI Confidence intervals; CS Corticosteroids; HR Hazard Ratio; OR Odds Ratio; SE 
Standard Error 
Figure 3 Random-effects meta-regression of log of mortality effect size and dose of 
corticosteroid expressed as methylprednisolone equivalent per day. 
Footnote for figure 3: Estimates from each included study are represented as circles. The 
area of each circle is inversely proportional to the variance of the log effect size, with 
circle area representative of the weight of each study. 
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